A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
← catalyst calendarNCT07142707 · readout in 72 d
Sponsored by MBX Biosciences (industry) · MBX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
124estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-03 | actual | When the study began enrolling |
| Primary completion | 2026-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: MBX 4291
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with Treatment Emergent Adverse Events (TEAEs)
measured The total duration of study participation for each participant including screening, treatment period, follow-up, and end of study visit will be up to 91 days in Part A, up to 99 days in Part B, and up to 148 days in Part C.
Permalink · MBX's whole pipeline · Catalyst calendar · Every registered study · What changed